Application of dexmedetomidine hydrochloride in preparation of medicine for treating anxiety and fear of pets

By developing dexmedetomidine hydrochloride oral-soluble membrane preparation, the problem of pet anxiety and fear drugs not absorbed quickly and have great side effects, achieving rapid absorption and efficient treatment, convenient administration, good palatability, and suitable for pet use. Filling the gap in the lack of compliant pet anti-anxiety products in China.

CN119055620APending Publication Date: 2024-12-03TIANJIN RINGPU BIO TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310767541.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-27
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing pet anxiety and fear drug preparations have problems such as rapid absorption, great side effects, and inconvenience in use. Foreign products are not suitable for pet use, and there is a lack of anti-anxiety products for compliant pets in China.

Method used

Develop a dexmedetomidine hydrochloride oral-soluble film preparation containing a therapeutically effective amount of dexmedetomidine hydrochloride, film forming agent, plasticizer and flavoring agent. Through specific proportion combination and preparation process, it can form good palatability. , fast-dissolving oral-soluble film agent.

Benefits of technology

It realizes rapid absorption and efficient treatment of dexmedetomidine hydrochloride, reduces side effects, is convenient to dosing, has good palatability, is suitable for pets, and simplifies the preparation process through industrial production processes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004306856750000041
    Figure BDA0004306856750000041
  • Figure BDA0004306856750000042
    Figure BDA0004306856750000042
  • Figure BDA0004306856750000051
    Figure BDA0004306856750000051
Patent Text Reader

Abstract

The invention provides application of dexmedetomidine hydrochloride in preparation of a pharmaceutical preparation for treating anxiety and fear of pets, and belongs to the technical field of veterinary pharmaceutical preparations. The pharmaceutical preparation is a dexmedetomidine hydrochloride oral soluble film agent and comprises the following components in percentage by weight: 1.0%-10% of dexmedetomidine hydrochloride, 40%-80% of a film-forming agent, 15.0%-35% of a plasticizer and 0.5%-5.0% of a flavoring agent. The dexmedetomidine hydrochloride oral soluble film is used for resisting anxiety and fear of pets caused by noise, travel, medical treatment, new environment and the like, has the advantages of good palatability, smooth surface, uniform drug distribution, good stability, quick dissolution, quick absorption, convenience in clinical use and the like, and has a wide application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of veterinary pharmaceutical preparations, and particularly relates to use of dexmedetomidine hydrochloride in preparing a pharmaceutical preparation for treating anxiety and fear in pets. Background Art

[0002] In the fast-paced, high-pressure modern society, keeping pets has become a widespread hobby, and pets have become important members in many families. According to the data published in the "2022 Pet Industry White Paper", the number of pet cats and dogs in urban areas across the country reached 116.55 million, a year-on-year increase of 3.7%. However, in the face of some situations such as thunder and lightning weather, loud noises at construction sites, fireworks, moving into new homes, foster care, hospital visits, car travel, etc., many pets will exhibit more abnormal behaviors, including repeated barking, scratching and biting furniture, running around, emotional mania and tension, etc., which will cause trouble to pet owners, and the pets themselves will also suffer from insomnia, loss of appetite and other symptoms due to emotional instability, which will endanger their health.

[0003] Currently, anti-anxiety drugs for dogs on the market abroad include: dexmedetomidine hydrochloride oral adhesive gel, fluoxetine chewable tablets, ipitutoin tablets, and clomipramine hydrochloride tablets. Tablets and chewable tablets are mostly used clinically, which are difficult to achieve autonomous feeding in clinical use, and the drug must be absorbed by the gastrointestinal tract after swallowing, which takes a long time to take effect, and some drugs have a first-pass effect or cause gastrointestinal irritation. However, there are no compliant pet-specific anti-anxiety products on the market in my country. Most pet owners will choose to give their pets human anti-anxiety drugs, such as diazepam, fluoxetine, and benzodiazepines, but the dosage form of human drugs is mostly tablets with poor palatability and large dosage specifications, which are not suitable for pets.

[0004] Dexmedetomidine hydrochloride is an α2-adrenergic receptor agonist with a relatively high α2 / α1 activity ratio (1620:1). It is considered to be a complete agonist of the α2 receptor, so it has a strong sedative effect and almost no cardiovascular side effects caused by α1 receptor activation. Dexmedetomidine hydrochloride has been used clinically in humans and pets for many years and is highly safe. The products currently on the market for pets include dexmedetomidine hydrochloride injection, which is mainly used as a sedative and analgesic for dogs and cats. It has a large specification and is not suitable for pet owners to use at home; dexmedetomidine hydrochloride oral gel is mainly used to relieve anxiety and fear in dogs, but the gel is not absorbed quickly enough and needs to be retained in the mouth for a certain period of time. During this period, the pet cannot eat or drink water, and there is a certain foreign body sensation in the mouth. Therefore, pet clinics urgently need an anti-anxiety product for pets that is rapidly absorbed, has good clinical anti-anxiety effects, has low side effects, and is easy to use.

[0005] As a new oral drug delivery dosage form, orodispersible film has the advantages of rapid disintegration in the oral cavity, thin thickness, light weight, folding and tensile resistance, easy to carry, and accurate dosage. It can overcome the shortcomings of orodispersible tablets being fragile, poor folding resistance, and poor dosage control of oral liquid preparations, and effectively solve the problem of poor compliance of special patients such as children, the elderly, and patients with mental illness. Advantages of orodispersible film: (1) Easy to take, no risk of choking, convenient and accurate administration, no need to swallow or chew with water; (2) Small size, taste masking, improved patient compliance, easy to carry and transport; (3) Rapid onset of action, improved bioavailability; when the drug enters the systemic circulation, it reduces the first-pass effect of the liver; (4) Low dose, minimal side effects. (5) Site specificity and local action. (6) Strong stability, which can avoid the destructive acidic environment of the stomach.

[0006] Therefore, there is a great clinical demand and advantage in preparing a dexmedetomidine hydrochloride orodispersible film preparation for the relief of anxiety and fear in pets. Summary of the invention

[0007] The present invention aims to solve the problems in the prior art and provide a dexmedetomidine hydrochloride orodispersible film preparation which has good palatability, dissolves quickly in the oral cavity and has good appearance.

[0008] The first aspect of the present invention provides the use of dexmedetomidine hydrochloride in preparing a pharmaceutical preparation for treating anxiety and fear in pets.

[0009] Preferably, the pharmaceutical preparation for treating anxiety and fear in pets is an orodispersible film preparation containing dexmedetomidine hydrochloride.

[0010] The anxiety and fear of the pets are mainly caused by noise, travel, medical treatment, new environment, etc.

[0011] Preferably, the pet's anxiety or fear is caused by noise.

[0012] The pets are selected from but not limited to dogs, cats, rabbits, mice, etc., and preferably the pets are dogs and cats.

[0013] The second aspect of the present invention provides a dexmedetomidine hydrochloride orodispersible film preparation, wherein the orodispersible film preparation comprises a therapeutically effective amount of dexmedetomidine hydrochloride, a film-forming agent, a plasticizer, and a flavoring agent.

[0014] Preferably, the mass percentages of the components in the orodispersible film are: 1.0%-10% dexmedetomidine hydrochloride, 40%-80% film-forming agent, 15%-35% plasticizer, and 0.5%-5.0% flavoring agent.

[0015] More preferably, the mass percentages of the components in the orodispersible film are: 5.0%-9.0% dexmedetomidine hydrochloride, 60%-70% film-forming agent, 18%-30% plasticizer, and 1.0%-3.0% flavoring agent.

[0016] Further preferably, the mass percentages of the components in the orodispersible film are: dexmedetomidine hydrochloride 6.0%-7.0%, film-forming agent 65%-70%, plasticizer 20%-25.0%, and flavoring agent 1.0%-3.0%.

[0017] The film-forming agent is one or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, copovidone VA64, polyvinyl alcohol, polyethylene oxide, povidone, polyethylene oxide, pectin, gelatin, sodium alginate, chitosan, chitosan derivatives, chitosan, and chitosan derivatives.

[0018] Preferably, the film-forming agent is composed of one of copovidone VA64 or povidone and one of chitosan, chitosan derivatives, chitosan, and chitosan derivatives.

[0019] Further preferably, the film-forming agent consists of copovidone VA64 and hydroxypropyl chitosan.

[0020] The plasticizer is one or more of mannitol, glycerol, polyethylene glycol, castor oil, acetylated monoglyceride, phthalate, triethyl citrate, sorbitol, and propylene glycol.

[0021] Preferably, the plasticizer is a water-soluble plasticizer, and the water-soluble plasticizer is one or more of mannitol, glycerol, polyethylene glycol, triethyl citrate, sorbitol, and propylene glycol.

[0022] Further preferably, the plasticizer is selected from polyethylene glycol and triethyl citrate.

[0023] The flavor corrector is one or more of beef flavor, chicken flavor, sucralose, chicken liver powder, and brewer's yeast powder.

[0024] Preferably, the flavoring agent is selected from beef flavor and sucralose.

[0025] A more preferred dexmedetomidine hydrochloride orodispersible film-forming agent is composed of 6.7% dexmedetomidine hydrochloride, 68.5% film-forming agent, 22.8% plasticizer and 2% flavoring agent.

[0026] The third aspect of the present invention provides a method for preparing a dexmedetomidine hydrochloride orodispersible film-dissolving agent, comprising the following steps:

[0027] (1) Preparation of auxiliary material solution: Add the film-forming agent to water while stirring, and continue stirring until dissolved, so that the concentration of the film-forming agent is 1% (W / V); add the plasticizer and continue stirring until dissolved, and then add the flavoring agent and stir to dissolve or disperse evenly to obtain an auxiliary material solution.

[0028] (2) Preparation of drug solution: Add dexmedetomidine hydrochloride to the auxiliary material solution of step (1), stir until dissolved, and vacuum degas to obtain a drug solution.

[0029] (3) Coating: Coat the drug solution on the backing material and control the coating thickness to 100-300 μm to obtain a film material.

[0030] (4) Drying: Dry the coated film at a temperature of 30 to 60°C.

[0031] (5) Packaging: Cut the dried film material into appropriate sizes and package them.

[0032] The beneficial effects of the present invention are:

[0033] 1. The present invention is an oral rapid absorption preparation of dexmedetomidine hydrochloride, which is convenient for clinical use compared with the injection solution, has the advantages of convenient administration, and pet owners can administer the medicine themselves at home.

[0034] 2. The dexmedetomidine hydrochloride orosoluble film prepared by the present invention can be rapidly disintegrated and absorbed in the oral cavity, and pets do not need to chew and swallow it, so the palatability is good, thereby improving the clinical compliance of pets.

[0035] 3. The dexmedetomidine hydrochloride orodispersible film prepared by the present invention has a rapid onset of action and improves bioavailability; when the drug enters the systemic circulation, the first-pass effect of the liver is reduced.

[0036] 4. The dexmedetomidine hydrochloride orodispersible film prepared by the present invention has low dosage, accurate administration and few side effects.

[0037] 5. The dexmedetomidine hydrochloride orodispersible film prepared by the present invention is independently packaged in single doses and is more hygienic than the dexmedetomidine hydrochloride oral gel available in foreign markets.

[0038] 6. The preparation process of the orodispersible film of the present invention is simple, easy to control, and suitable for industrial production.

[0039] 7. The selection of key film-forming agents in the present invention not only overcomes the problem that the orodispersible film is easily broken, but also has moderate toughness, is easy to cut, package, store and transport, and has the effect of inhibiting crystallization during the stability storage process. DETAILED DESCRIPTION

[0040] The above contents will be further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter being limited to the following embodiments. All technologies realized based on the contents of the present invention are within the scope.

[0041] Example 1

[0042] The formulation and dosage of a dexmedetomidine hydrochloride orodispersible film are as follows:

[0043]

[0044] Example 2

[0045] The formulation and dosage of a dexmedetomidine hydrochloride orodispersible film are as follows:

[0046]

[0047]

[0048] Example 3

[0049] The formulation and dosage of a dexmedetomidine hydrochloride orodispersible film are as follows:

[0050] Example 4

[0051] The formulation and dosage of a dexmedetomidine hydrochloride orodispersible film are as follows:

[0052]

[0053] Example 5

[0054] The formulation and dosage of a dexmedetomidine hydrochloride orodispersible film are as follows:

[0055]

[0056]

[0057] Taking 10 g per batch as an example, the preparation method of dexmedetomidine hydrochloride orodispersible film in Examples 1-5 comprises the following steps:

[0058] (1) Preparation of auxiliary material solution: Add the formulated amount of hydroxypropyl chitosan into water, stir until dissolved, then add copovidone VA64 under stirring, stir until dissolved, so that the concentration of the film-forming agent is 1% (W / V). Add the formulated amount of triethyl citrate, stir until dissolved, then add beef flavor and sucralose, stir until dissolved, and obtain auxiliary material solution.

[0059] (2) Preparation of drug solution: Add dexmedetomidine hydrochloride to the solution of step (1), stir until dissolved, and vacuum degas to obtain a drug solution.

[0060] (3) Coating: Coat the drug solution on the backing material and control the coating thickness to be about 200 μm to obtain a film material.

[0061] (4) Drying: Dry the coated film at a drying temperature of 50°C.

[0062] (5) Packaging: Cut the dried film material into appropriate sizes and package them.

[0063] Comparative Example 1

[0064] The formulation and dosage of a dexmedetomidine hydrochloride orodispersible film are as follows:

[0065]

[0066] Comparative Example 2

[0067] The formulation and dosage of a dexmedetomidine hydrochloride orodispersible film are as follows:

[0068]

[0069]

[0070] Comparative Example 3

[0071] The formulation and dosage of a dexmedetomidine hydrochloride orodispersible film are as follows:

[0072]

[0073] Taking 10 g per batch as an example, the preparation method of dexmedetomidine hydrochloride orodispersible film in Comparative Examples 1-3 comprises the following steps:

[0074] (1) Preparation of auxiliary material solution: Add the prescribed amount of chitosan to water, stir until dissolved, then add hydroxypropyl methylcellulose under stirring, stir until dissolved, so that the concentration of the film-forming agent is 1% (W / V). Add the prescribed amount of polyethylene glycol or glycerol, stir until dissolved, then add beef flavor and sucralose, stir until dissolved, and obtain auxiliary material solution.

[0075] (2) Preparation of drug solution: Add dexmedetomidine hydrochloride to the solution of step (1), stir until dissolved, and vacuum degas to obtain a drug solution.

[0076] (3) Coating: The drug solution is coated on the backing material, and the coating thickness is controlled to be about 200 μm to obtain a film material.

[0077] (4) Drying: Dry the coated film at a drying temperature of 50°C.

[0078] (5) Packaging: Cut the dried film material into appropriate sizes and package them.

[0079] Example 6 Appearance, tensile strength, dissolution, and drug precipitation of orally dissolving film preparations

[0080] Table 1 Appearance, tensile strength, dissolution rate and drug precipitation of orodispersible film preparations

[0081]

[0082]

[0083] In Comparative Example 1, the amount of the film-forming agent is low and the amount of the plasticizer polyethylene glycol is high, so that the film cannot be formed;

[0084] In the embodiment, hydroxypropyl chitosan is added as a film-forming agent because it has the property of rapid dissolution in water and has the functions of a disintegrant and a pore-forming agent. After the orodissolving film contacts saliva, the hydroxypropyl chitosan rapidly dissolves in the saliva, driving the disintegration of the orodissolving film and the dissolution of the drug. In Example 1, the amount of hydroxypropyl chitosan added is relatively small, so the dissolution is relatively slow in 5 minutes;

[0085] The tensile strength of the orodispersible film is related to the selection of the film former, the plasticizer, and the ratio of the film former to the plasticizer. The data show that the orodispersible film prepared in Example 2 using a combination of copolyvidone VA64 and hydroxypropyl chitosan as the film former has a relatively strong overall tensile strength. The tensile strength of the orodispersible film in Example 2 is relatively low due to the excessive amount of plasticizer used.

[0086] In the embodiment, copolyvidone VA64 is used as a film-forming agent, which can inhibit the crystallization of the drug during the stability storage process. When hydroxypropyl methylcellulose or a mixture thereof and chitosan is used as a film-forming agent, the crystal inhibition effect cannot be achieved, and white crystalline substances are precipitated during the stability storage process. At the same time, chitosan is insoluble in water, and hydroxypropyl methylcellulose needs to be swollen in water before being dissolved, thereby prolonging the dissolution time of the drug, which is not conducive to clinical use.

[0087] Example 7 Experimental study on the therapeutic effect of noise-induced anxiety and fear in pet dogs

[0088] Example 3 was selected to evaluate the effect of dexmedetomidine hydrochloride orodispersible film on treating anxiety and fear in dogs. A total of 16 dogs diagnosed with noise phobia according to the Lincoln Sound Sensitivity Scale were included in the evaluation, and the 16 dogs were randomly divided into two groups, a blank control group (administered with placebo) and a treatment group (administered with dexmedetomidine hydrochloride orodispersible film (0.3 mg / kg / )). Two days before the expected noise event (New Year's Eve), dexmedetomidine hydrochloride orodispersible film or placebo was started for treatment, and the pet owners were required to observe the dogs at fixed time points and perform anxiety scale (LCAS) scoring.

[0089] Table 2 Scoring criteria for anxiety and fear in dogs treated with dexmedetomidine hydrochloride orodispersible film

[0090]

[0091] The test results of dogs using Example 3 and placebo are as follows:

[0092] Table 3 Evaluation of the effect of dexmedetomidine hydrochloride orodispersible film on anxiety and fear in dogs

[0093]

[0094]

[0095] The test results showed that the scores of dogs treated with dexmedetomidine hydrochloride orodispersible film were lower than those of the blank control group, indicating that dexmedetomidine hydrochloride has a significant effect on the treatment of anxiety and fear in dogs.

[0096] The present invention is described above by way of example. It should be noted that, without departing from the core of the present invention, any simple deformation, modification or other equivalent replacement that can be made by those skilled in the art without inventive effort falls within the protection scope of the present invention.

Claims

1. Use of dexmedetomidine hydrochloride in the preparation of a pharmaceutical preparation for treating anxiety and fear in pets, characterized in that: The pharmaceutical preparation is an orodispersible film containing dexmedetomidine hydrochloride.

2. The use according to claim 1, characterized in that The pet anxiety and fear are caused by noise, travel, medical treatment and new environment.

3. The use according to claim 2, characterized in that: The pet anxiety and fear are caused by noise.

4. A dexmedetomidine hydrochloride orodispersible film-forming agent, characterized in that: The orodispersible film comprises dexmedetomidine hydrochloride, a film former, a plasticizer and a flavoring agent; the mass percentage of each component in the orodispersible film is: 1.0%-10% of dexmedetomidine hydrochloride, 40%-80% of the film former, 15%-35% of the plasticizer and 0.5%-5.0% of the flavoring agent.

5. The orodispersible film preparation according to claim 4, characterized in that: The mass percentages of the components in the orodispersible film preparation are as follows: 5.0%-9.0% of dexmedetomidine hydrochloride, 60%-70% of a film former, 18%-30% of a plasticizer, and 1.0%-3.0% of a flavoring agent.

6. The orodispersible film preparation according to claim 5, characterized in that The mass percentages of the components in the orodispersible film preparation are: 6.0%-7.0% of dexmedetomidine hydrochloride, 65%-70% of a film former, 20%-25.0% of a plasticizer, and 1.0%-3.0% of a flavor corrective.

7. The orodispersible film according to any one of claims 4 to 6, characterized in that: The film-forming agent is one or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, copovidone VA64, polyvinyl alcohol, polyethylene oxide, povidone, polyethylene oxide, pectin, gelatin, sodium alginate, chitosan, chitosan derivatives, chitosan, and chitosan derivatives.

8. The orodispersible film preparation according to claim 7, characterized in that: The film-forming agent is composed of one of copolyvidone VA64 or povidone and one of chitosan, chitosan derivatives, chitosan, and chitosan derivatives.

9. The orodispersible film preparation according to claim 8, characterized in that The film-forming agent consists of copolyvidone VA64 and hydroxypropyl chitosan.

10. The orodissolving film according to any one of claims 4 to 6, characterized in that: The plasticizer is a water-soluble plasticizer, and the water-soluble plasticizer is one or more of mannitol, glycerol, polyethylene glycol, triethyl citrate, sorbitol, and propylene glycol; the flavoring agent is one or more of beef flavor, chicken flavor, sucralose, chicken liver powder, and brewer's yeast powder.